"2210-63-1" OR "" - Search Results

Year	Number of Results
1963	1
1964	2
1965	1
1971	1
1980	1
1981	1
1984	2
1985	1
1986	3
1987	2
1991	1
1992	2
1993	4
1994	1
1995	1
1997	1
2024	0

1

The interaction of mofebutazone with furosemide.

Matthei U, Grabensee B, Loew D. Matthei U, et al. Curr Med Res Opin. 1987;10(9):638-44. doi: 10.1185/03007998709112418. Curr Med Res Opin. 1987. PMID: 3481307 Clinical Trial.

2

Pharmacokinetics of [4-14C] mofebutazone after oral administration in man.

Kassem MA, Schulte KE. Kassem MA, et al. Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):223-7. doi: 10.1007/BF03189645. Eur J Drug Metab Pharmacokinet. 1984. PMID: 6519123

3

Structure of phenylbutazone and mofebutazone in the crystalline state and in solution.

Paradies HH. Paradies HH. J Pharm Sci. 1987 Dec;76(12):920-9. doi: 10.1002/jps.2600761217. J Pharm Sci. 1987. PMID: 3440938

4

Antioxidative properties of phenazone derivatives: differentiation between phenylbutazon and mofebutazon.

Schneider I, Elstner EF. Schneider I, et al. Z Naturforsch C J Biosci. 1993 Jul-Aug;48(7-8):542-4. doi: 10.1515/znc-1993-7-802. Z Naturforsch C J Biosci. 1993. PMID: 8216610 Free article.

5

Influence of phenylbutazone, mofebutazone and aspirin on the pharmacokinetics of dexamethasone in the rat.

Kassem MA, Schulte KE. Kassem MA, et al. Eur J Drug Metab Pharmacokinet. 1981;6(1):11-20. doi: 10.1007/BF03189511. Eur J Drug Metab Pharmacokinet. 1981. PMID: 7250148

6

Determination of mofebutazone and its 4-hydroxy metabolite in plasma and urine by high-performance liquid chromatography.

Delbeke FT, Debackere M. Delbeke FT, et al. J Chromatogr. 1986 Nov 21;369(2):440-4. doi: 10.1016/s0021-9673(00)90155-9. J Chromatogr. 1986. PMID: 3805210 No abstract available.

7

Delayed-type hypersensitivity to mofebutazone underlying a severe drug reaction.

Walchner M, Rueff F, Przybilla B. Walchner M, et al. Contact Dermatitis. 1997 Jan;36(1):54-5. doi: 10.1111/j.1600-0536.1997.tb00926.x. Contact Dermatitis. 1997. PMID: 9034692 No abstract available.

8

High-resolution solid-state carbon-13 nuclear magnetic resonance spectra of mofebutazone, phenylbutazone, and oxyphenbutazone in relation to X-ray crystallographic data.

Stoltz M, Oliver DW, Wessels PL, Chalmers AA. Stoltz M, et al. J Pharm Sci. 1991 Apr;80(4):357-62. doi: 10.1002/jps.2600800415. J Pharm Sci. 1991. PMID: 1865336

9

Disposition of [4-14C]mofebutazone in the rat.

Bass VM, Mrongovius RI, Schulte KE. Bass VM, et al. Eur J Drug Metab Pharmacokinet. 1980;5(4):201-6. doi: 10.1007/BF03189465. Eur J Drug Metab Pharmacokinet. 1980. PMID: 7250143

10

Influence of mofebutazone in comparison to phenylbutazone on the adenosine triphosphate level of polymorphonuclear cells and their migration.

Partsch G. Partsch G. Arzneimittelforschung. 1992 Nov;42(11):1336-8. Arzneimittelforschung. 1992. PMID: 1492846

Two pyrazolon derivatives--mofebutazone (CAS 2210-63-1) and phenylbutazone (CAS 50-33-9)--were compared as to their effects on the adenosine triphosphate (ATP) level of polymorphonuclear cells (PMNs) and their response to the migration of these cells. ...

Two pyrazolon derivatives--mofebutazone (CAS 2210-63-1) and phenylbutazone (CAS 50-33-9)--were compared as to their eff …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year